This website uses cookies for usage measurement and traffic analysis purposes.
By clicking the "Agree" button or continuing to browse this site, you consent to the use of cookies.
For more details, please refer to the Privacy Policy
(opens in a new window).
| Department | Department of Head and Neck, Esophageal Medical Oncology, Department of Gastrointestinal Medical Oncology |
|---|---|
| Specialized Treatment | Chemotherapy and chemoradiotherapy for oesophageal, esophagogastric, and gastric cancer |
Dr. Ken Kato is a medical oncologist with a primary focus on improving outcomes for patients with oesophageal, esophagogastric, and gastric cancers. His work spans the development of innovative chemotherapies and multimodality treatments for metastatic and early-stage cancers. He has been pivotal in clinical trials, such as JCOG0502, which demonstrated the non-inferiority of chemoradiotherapy to surgery for stage I oesophageal squamous carcinoma, and JCOG1109, a study on neoadjuvant therapy for resectable oesophageal squamous cell carcinoma. He also contributes to international phase III trials involving immune-checkpoint inhibitors. His ultimate goal is to develop advanced therapies and translational research to better serve cancer patients.
